Related by context. All words. (Click for frequent words.) 79 metastatic colorectal cancer 78 NSCLC 74 metastatic breast cancer 73 metastatic renal cell carcinoma 71 hormone refractory prostate cancer 71 mRCC 70 metastatic RCC 70 mCRC 69 pemetrexed 69 docetaxel 69 gemcitabine 69 gefitinib 68 HRPC 68 cell lung cancer 68 HER2 positive metastatic breast 68 erlotinib 67 mCRC patients 67 sorafenib 67 temozolomide 67 sunitinib 67 recurrent NSCLC 67 capecitabine 67 vandetanib 66 metastatic pancreatic cancer 66 dacarbazine 66 metastatic melanoma 66 heavily pretreated 66 renal cell carcinoma 66 HER2 positive breast cancer 66 temsirolimus 66 axitinib 65 cetuximab 65 chemotherapy regimens 65 bevacizumab 65 metastatic NSCLC 65 free survival PFS 65 bendamustine 65 brain metastases 65 metastatic disease 65 chlorambucil 65 chronic lymphocytic leukemia CLL 65 unresectable 65 castration resistant prostate cancer 65 indolent NHL 65 FOLFIRI 65 docetaxel chemotherapy 65 metastatic CRC 64 hepatocellular carcinoma HCC 64 trastuzumab 64 KRAS wild 64 metastatic CRPC 64 refractory multiple myeloma 64 plus gemcitabine 64 CLL 64 Vectibix 64 malignant pleural mesothelioma 64 vinorelbine 64 metastatic renal cell 64 rituximab 64 prostate cancer HRPC 64 unresectable stage 63 carboplatin 63 HCV infected 63 platinum refractory 63 chemotherapy regimen 63 follicular lymphoma 63 carboplatin paclitaxel 63 IMGN# 63 remission induction 63 cisplatin 63 gemcitabine chemotherapy 63 Amrubicin 63 diagnosed multiple myeloma 63 decitabine 63 sorafenib Nexavar 63 Torisel 63 metastatic colon cancer 63 monotherapy 63 metastatic hormone refractory 63 stage IIIB IV 63 refractory NSCLC 63 refractory CTCL 63 prostate cancer CRPC 63 HER2 positive 63 stage IIIB 63 B CLL 63 lymphoma CTCL 63 relapsed refractory multiple myeloma 63 resistant ovarian cancer 63 relapsed SCLC 63 Fludara 63 Taxotere ® 63 chemoradiation 63 hepatocellular cancer 63 low dose cytarabine 63 non squamous NSCLC 62 relapsed ovarian cancer 62 bortezomib 62 FOLFOX 62 FOLFOX4 62 HCV infection 62 amrubicin 62 plus dexamethasone 62 Tarceva 62 sorafenib Nexavar ® 62 gastrointestinal stromal tumor GIST 62 pegylated interferon alpha 62 liver metastases 62 pegylated interferon 62 recurrent GBM 62 IV melanoma 62 glufosfamide 62 IRESSA 62 SCCHN 62 leukemia CLL 62 biologic therapy 62 acute myelogenous leukemia AML 62 multiple myeloma MM 62 dasatinib 62 adjuvant therapy 62 pegylated liposomal doxorubicin 62 FOLFOX regimen 62 pancreatic NET 62 refractory CLL 61 Metastatic Colorectal Cancer 61 multiple myeloma 61 cutaneous T cell 61 chronic myeloid leukemia CML 61 azacitidine 61 OncoVEX GM CSF 61 solid tumors 61 acute myeloid leukemia AML 61 Doxil ® 61 Pemetrexed 61 Tarceva erlotinib 61 metastatic 61 topotecan 61 DMARD 61 IV NSCLC 61 unresectable locally advanced 61 advanced unresectable 61 DLBCL 61 pancreatic neuroendocrine tumors 61 pancreatic adenocarcinoma 61 fludarabine 61 Taxotere 61 refractory metastatic colorectal cancer 61 EGFR mutation 61 refractory AML 61 neoadjuvant chemotherapy 61 medullary thyroid cancer 61 metastatic GIST 61 trabectedin 61 leukemia AML 61 stage IIIb IV 61 heavily pretreated patients 61 Halaven 61 gastric cancer 61 sunitinib malate 61 HCV genotype 1 61 recurrent glioblastoma 61 nab paclitaxel 61 bevacizumab Avastin 60 cytotoxic chemotherapy 60 adjuvant chemotherapy 60 T#I mutation 60 afatinib 60 cisplatin chemotherapy 60 metastatic HRPC 60 peginterferon 60 cancer mCRC 60 FOLOTYN 60 irinotecan 60 idiopathic pulmonary fibrosis IPF 60 adalimumab 60 taxane chemotherapy 60 VIDAZA 60 anthracycline taxane 60 lamivudine 60 metastatic cancer 60 standard chemotherapy regimen 60 metastatic castration resistant 60 Acute Myeloid Leukemia AML 60 nonsquamous 60 phase IIb clinical 60 nilotinib 60 glioblastoma 60 ipilimumab 60 paclitaxel carboplatin 60 registrational trial 60 lupus nephritis 60 relapsed multiple myeloma 60 Xeloda 60 relapsed CLL 60 Genasense ® 60 pegylated interferon alfa 2a 60 pomalidomide 60 systemic ALCL 60 ASA# 60 taxane 60 metastatic prostate cancer 60 EGFR mutations 60 interferon alfa 2a 60 peginterferon alfa 2a 60 metastatic SCCHN 60 carfilzomib 59 dacarbazine DTIC 59 sapacitabine 59 oxaliplatin 59 relapsed refractory 59 docetaxel Taxotere 59 erlotinib Tarceva ® 59 TORISEL 59 CHOP chemotherapy 59 chemoradiotherapy 59 standard chemotherapy regimens 59 XELOX 59 abiraterone acetate 59 TEMODAL 59 hepatocellular carcinoma 59 advanced hepatocellular carcinoma 59 eribulin 59 randomized Phase III 59 nonsmall cell lung cancer 59 anti leukemic 59 tamibarotene 59 5-FU/LV 59 relapsing multiple sclerosis 59 imatinib 59 daunorubicin 59 forodesine 59 symptomatic BPH 59 Irinotecan 59 Bevacizumab 59 advanced nonsquamous NSCLC 59 interferon alfa 59 lintuzumab 59 cytarabine 59 panitumumab 59 cell lymphoma CTCL 59 Erlotinib 59 Gemzar ® 59 lapatinib 59 anthracyclines 59 Taxotere R 59 hematologic malignancies 59 IV metastatic melanoma 59 EGFR expressing mCRC 59 taxane therapy 59 elacytarabine 59 EGFR mutation positive 59 docetaxel Taxotere R 59 myelodysplastic syndromes MDS 59 anti TNF 59 imatinib therapy 59 relapsing MS 59 gefitinib Iressa 59 soft tissue sarcoma 59 androgen independent 59 aflibercept 59 plus prednisone 59 dasatinib Sprycel ® 59 recurrent ovarian cancer 59 GIST 59 metastatic kidney 59 gemcitabine carboplatin 59 mycophenolate mofetil 59 Jevtana 58 imatinib Gleevec ® 58 gastrointestinal stromal tumors 58 adecatumumab 58 HGS ETR1 58 EGFR TKI 58 Velcade bortezomib 58 HER2 negative 58 chronic ITP 58 locoregional 58 chronic hepatitis C. 58 tyrosine kinase inhibitors 58 cilengitide 58 fluoropyrimidine 58 superficial bladder cancer 58 pazopanib 58 preoperative chemotherapy 58 pegfilgrastim 58 Gemcitabine 58 irinotecan chemotherapy 58 paclitaxel chemotherapy 58 chronic HCV 58 OPAXIO 58 eribulin mesylate 58 iniparib 58 oblimersen 58 follicular lymphoma FL 58 gemcitabine Gemzar 58 recurrent glioblastoma multiforme 58 fallopian tube carcinoma 58 relapsing remitting multiple sclerosis 58 Yervoy 58 soft tissue sarcomas 58 TYKERB 58 pertuzumab 58 adjuvant tamoxifen 58 Dacogen injection 58 bevacizumab Avastin ® 58 FOLFIRI alone 58 KRAS mutations occur 58 clofarabine 58 KRAS status 58 receptor tyrosine kinase inhibitor 58 paclitaxel 58 cabazitaxel 58 non squamous 58 dasatinib Sprycel 58 biliary tract cancer 58 RG# [001] 58 neoadjuvant treatment 58 cetuximab Erbitux ® 58 IV malignant melanoma 58 Cloretazine ® 58 IIIB NSCLC 58 ELACYT 58 chronic HCV infection 58 Free Survival PFS 58 Herceptin trastuzumab 58 Hycamtin 58 alvespimycin 58 RRMS patients 58 estramustine 58 ZACTIMA 58 untreated multiple myeloma 58 5 FU 58 melphalan prednisone 58 hormone receptor positive 58 idarubicin 58 recurrent colorectal cancer 58 perifosine 58 neoadjuvant 58 Tamibarotene 58 CMV disease 58 Clolar 58 imatinib resistant 58 adjuvant radiation 58 mitoxantrone 58 Revlimid lenalidomide 58 unresectable Stage III 58 goserelin 58 neoadjuvant therapy 58 Sorafenib 58 Nexavar sorafenib 58 KRAS mutant tumors 57 refractory ovarian cancer 57 regorafenib 57 5 fluorouracil 57 EGFR expressing 57 chemotherapeutic agent 57 metastatic colorectal 57 Bortezomib 57 Median survival 57 metastatic malignant melanoma 57 PegIFN RBV 57 metastatic squamous cell carcinoma 57 colorectal cancer 57 Fludarabine 57 TKI therapy 57 durable remissions 57 metastatic lung cancer 57 palifosfamide 57 peg IFN 57 BR.# 57 virologic failure 57 glioblastoma multiforme GBM 57 HCV SPRINT 57 enzastaurin 57 relapsed MM 57 Gefitinib 57 ERBITUX 57 TRISENOX 57 LUX Lung 57 diagnosed GBM 57 XYOTAX 57 VELCADE melphalan 57 ribavirin therapy 57 hepatitis C genotype 57 cytotoxic therapy 57 ADXS# 57 CTCL 57 REVLIMID 57 assessing T DM1 57 TREANDA 57 neuroendocrine tumors 57 ribavirin RBV 57 Platinol 57 alkylating agent 57 stage IIIb 57 FTY# 57 T DM1 57 plus ribavirin 57 refractory metastatic 57 interferon therapy 57 HER2 + 57 operable breast cancer 57 BEXXAR 57 Genasense 57 non metastatic osteosarcoma 57 metastatic castrate resistant 57 Peginterferon 57 5FU 57 Sandostatin LAR 57 oral ridaforolimus 57 hypomethylating agents 57 mapatumumab 57 APTIVUS r 57 vemurafenib 57 CIMZIA ™ 57 AVASTIN 57 entecavir 57 Allovectin 7 57 Ceflatonin 57 Hodgkin lymphoma NHL 57 autoantibody positive 57 Cloretazine 57 bone metastases 57 protease inhibitor PI 57 anthracycline containing 57 dacarbazine chemotherapy 57 abiraterone 57 Amigal 57 refractory PTCL 57 tocilizumab 57 Avastin bevacizumab 57 Allovectin 7 ® 57 posaconazole 57 ganetespib 57 docetaxel Taxotere ® 57 Nexavar 57 Aflibercept 57 localized prostate cancer 57 imatinib Gleevec 57 leukemia ALL 57 tumors GIST 57 DCVax R Brain 57 Troxatyl 57 castrate resistant prostate cancer 57 Xeloda capecitabine 57 vicriviroc 57 relapsed GBM 57 VELCADE 56 PXD# 56 bone metastasis 56 cetuximab Erbitux 56 INCB# [001] 56 FOLFOX6 56 hepatitis C HCV 56 Folfox 56 trastuzumab Herceptin R 56 trabedersen 56 TACE 56 FluCAM 56 mTOR inhibitor 56 tumor recurrence 56 Voreloxin 56 nilotinib Tasigna ® 56 PEG interferon 56 HCV genotype 56 CR# vcMMAE 56 IMA# 56 boosted protease inhibitor 56 Pegasys ® 56 Gleevec resistant 56 Cell Lung Cancer 56 HuMax CD4 56 ixabepilone 56 adult chronic ITP 56 HSCT 56 imetelstat 56 chemotherapeutic regimens 56 metastatic colorectal carcinoma 56 GvHD 56 Neoadjuvant 56 basal cell carcinoma BCC 56 Annamycin 56 DMARDs 56 refractory APL 56 YONDELIS 56 metastatic gastric 56 aflibercept VEGF Trap 56 Hepatocellular Carcinoma HCC 56 tamoxifen therapy 56 complete remissions 56 XL# [003] 56 MabThera 56 prostate cancer mCRPC 56 Afinitor 56 anti TNF alpha 56 interferon 56 Sprycel dasatinib 56 Mylotarg 56 Intravenous CP 56 chronic ITP patients 56 rituximab refractory 56 relapsed Hodgkin lymphoma 56 recurrent prostate cancer 56 lumiliximab 56 colorectal liver metastases 56 Aplidin 56 talabostat 56 Cytoxan 56 null responder HCV 56 Alemtuzumab 56 SUTENT 56 PROSTVAC ® 56 ofatumumab 56 Navelbine ® 56 paclitaxel Taxol R 56 postoperative chemotherapy 56 relapsed AML 56 cetuximab Erbitux R 56 haematologic malignancies 56 Dasatinib 56 Tavocept 56 adriamycin 56 Tarceva TM 56 panitumumab Vectibix 56 tumor shrinkage 56 anti angiogenic therapy 56 gemcitabine cisplatin 56 glioblastomas 56 sipuleucel T 56 acute ischemic stroke 56 FOLFOX chemotherapy 56 Traficet EN 56 cediranib 56 doxorubicin HCl liposome injection 56 BRIM2 56 Acute Myeloid Leukemia 56 ACTEMRA TM 56 BRAF mutation 56 seliciclib 56 Metastatic Breast Cancer 56 BRAF V# mutation 56 chemotherapies 56 squamous histology 56 Rituxan rituximab 56 RoACTEMRA 56 Pfizer Sutent 56 lenalidomide 56 diagnosed glioblastoma multiforme 56 evaluating picoplatin 56 AEG# 56 SPRYCEL ® 56 HCV RESPOND 2 56 MYDICAR ® 56 differentiated thyroid 56 anthracyclines taxanes 56 albinterferon alfa 2b 56 nucleoside analogue 56 anthracycline 56 CR nPR 55 infliximab 55 CML CP 55 refractory chronic lymphocytic 55 vinca alkaloids 55 Alimta 55 Ixempra 55 NNRTI 55 APTIVUS 55 relapsing remitting MS RRMS 55 stage IIIA 55 aHUS 55 daclizumab 55 concurrent chemoradiation 55 invasive candidiasis 55 squamous cell histology 55 Taxotere docetaxel 55 zoledronic acid 55 tyrosine kinase inhibitor 55 chronic hepatitis B. 55 XGEVA 55 CLL SLL 55 AP# [003] 55 follicular non 55 clinically localized prostate 55 raltegravir 55 carcinoid tumors 55 ® cetuximab 55 Rituxan 55 Perifosine 55 follicular NHL 55 abatacept 55 valopicitabine 55 untreated de novo 55 Gleevec imatinib 55 BRIM3 55 infusional 5-FU/LV 55 virologic response 55 Vectibix monotherapy 55 mutated KRAS 55 alfa 2a 55 Copegus ribavirin 55 Apaziquone 55 paclitaxel Taxol ® 55 phase Ib 55 Bezielle 55 gastric cancers 55 myeloma 55 Targretin 55 Nexavar ® 55 interferon gamma 1b 55 custirsen 55 hematological cancers 55 distant metastasis 55 sustained virologic response 55 BARACLUDE ® 55 L MTP PE 55 Peginterferon alfa 2b 55 achieve sustained virologic 55 Neulasta ® 55 picoplatin 55 Peg IFN 55 lenalidomide Revlimid R 55 Elitek 55 mcg albinterferon alfa 2b 55 pralatrexate 55 DMARD therapy 55 cytogenetic responses 55 recurrent malignant glioma 55 peg interferon 55 baminercept 55 resectable 55 taxane refractory 55 cholangiocarcinoma 55 ALIMTA 55 sustained virological response 55 chronic angina 55 cytarabine daunorubicin 55 CANCIDAS 55 VFEND 55 metastatic carcinoma 55 Folotyn 55 evaluating Xcytrin 55 FOLFIRINOX 55 Alocrest 55 resected pancreatic cancer 55 BCIRG 55 romiplostim 55 PREZISTA r 55 octreotide LAR 55 IFN α 55 fluorouracil 55 dose cytarabine 55 MabCampath 55 oral clodronate 55 androgen deprivation 55 vismodegib 55 tivozanib 55 ACZ# 55 bosutinib 55 prior chemotherapy regimens 55 BAY #-# 55 obatoclax 55 anastrozole 55 PEGylated interferon beta 1a 55 randomized Phase 55 doxorubicin 55 pegylated interferon alfa 55 disease progression 55 lapatinib Tykerb 55 Tykerb 55 pain palliation 55 depsipeptide 55 cyclophosphamide chemotherapy 55 thalidomide Thalomid 55 evaluating T DM1 55 DAPT 55 invasive aspergillosis 55 chemotherapy docetaxel 55 telaprevir dosed 55 5 fluorouracil leucovorin 55 glatiramer acetate 55 Quinamed 55 Rituximab 55 FOLPI 55 colorectal cancer liver metastases 55 elotuzumab 55 tiotropium 55 chemotherapeutic regimen 55 olaparib 55 ritonavir boosted 55 IMC A# 55 Trastuzumab 55 Carboplatin 55 malignancies 55 pancreatic carcinoma 55 Evoltra ® 55 ASCT 55 interferon beta 1a 55 entinostat 55 R sorafenib tablets 55 Proxinium TM 55 refractory HL 55 5 FU leucovorin 55 Phase Ib 55 refractory chronic myeloid 55 Xanafide 55 patients evaluable 55 PROSTVAC TM 55 myelodysplastic syndrome MDS 55 Phase Ib II 55 evaluable patients 54 refractory lymphoma 54 MPS IVA 54 hormonal therapy 54 ORENCIA ® 54 Hodgkin lymphoma HL 54 trastuzumab Herceptin ® 54 EGFR inhibitors 54 refractory acute myeloid 54 interferon ribavirin 54 capecitabine Xeloda 54 Uricase PEG 54 metastatic HER2 negative 54 Novartis Gleevec 54 TTF Therapy 54 treatment naïve genotype 54 anti EGFR antibody 54 complete cytogenetic response 54 HCV 54 Arranon 54 relapsing remitting 54 metastatic malignant 54 candidemia 54 dose dexamethasone 54 romidepsin 54 Sunitinib 54 Cloretazine R VNP#M 54 HBeAg negative 54 taxanes 54 antibody MAb 54 Follicular Lymphoma 54 azathioprine 54 chemotherapy 54 Surgical resection 54 evaluating tivozanib 54 refractory gout 54 figitumumab 54 voreloxin 54 GISTs 54 gastrointestinal stromal tumors GIST 54 Omnitarg 54 pegylated interferons 54 K ras mutations 54 KRAS mutations 54 Ozarelix 54 TKIs 54 XL# SAR# 54 Pegasys plus Copegus 54 Sutent 54 Navelbine 54 Cimzia TM 54 GVAX 54 prospectively defined 54 efalizumab 54 PSMA ADC 54 chronic lymphocytic leukemia 54 Phenoptin 54 PegIFN 54 MyVax R 54 TMC# C# 54 exemestane 54 Pixantrone 54 Fludara ® 54 visilizumab 54 ZYVOX 54 INC# 54 Ranibizumab 54 Xcytrin 54 cART 54 EOquin 54 hematological malignancies 54 AMN# [001] 54 acute promyelocytic leukemia APL 54 HGS# 54 nitazoxanide 54 HBeAg positive patients 54 chemotherapy cisplatin 54 leucovorin 54 MabThera Rituxan 54 Advaxis Phase 54 systemic lupus erythematosus SLE 54 NRTIs 54 UPLYSO 54 inoperable pancreatic cancer 54 ER CHOP 54 myelofibrosis 54 paclitaxel Taxol 54 EGFR tyrosine kinase inhibitors 54 acute leukemias 54 CRp 54 Stage IIIb IV 54 elagolix 54 atypical Hemolytic Uremic Syndrome 54 refractory Hodgkin lymphoma 54 fondaparinux 54 docetaxel prednisone 54 relapsing forms 54 CLL8 54 trastuzumab Herceptin 54 untreated AML 54 systemic lupus erythematosus 54 Xyotax 54 Avastin 54 Pegylated Interferon 54 PKC# 54 adalimumab Humira 54 antitumor activity 54 acute myeloid leukemia 54 Erbitux 54 refractory myeloma 54 PROVENGE 54 immunosuppressant 54 Erbitux cetuximab 54 low dose dexamethasone 54 AVOREN 54 Vandetanib 54 hepatic metastases 54 oral vancomycin 54 PegIntron 54 viral kinetics 54 VPRIV 54 PLX# 54 Provenge 54 T#I [002] 54 achieved ACR# 54 Kit CD# positive 54 HNSCC 54 investigational compound 54 SHPT 54 Revlimid 54 fluconazole 54 lung metastases 54 Lenalidomide 54 mutated KRAS gene 54 resminostat 54 adefovir 54 velafermin 54 micafungin 54 IRX 2 54 atrial fibrillation budiodarone ATI 54 Doxil 54 hormone refractory metastatic prostate 54 tesetaxel 54 EGFR TKIs 54 null responder 54 Myelodysplastic Syndrome MDS 54 cisplatin vinorelbine 54 CIMZIA TM 54 Docetaxel 54 GW# [003] 54 SJIA 54 tyrosine kinase inhibitors TKIs 54 non resectable 54 dose escalation Phase 54 placebo controlled Phase 54 antiretroviral naive 54 biochemical recurrence 54 Acute Myelogenous Leukemia AML 54 TMC# [001] 54 acute PAO 54 metastatic breast 54 Phase 2a trial 54 mitomycin 54 Everolimus 54 Velcade 54 Temsirolimus 54 chronic hepatitis C 54 Sutent sunitinib 54 Adjuvant chemotherapy 54 TroVax ® 54 belatacept 54 pegylated interferon alfa 2b 54 refractory colorectal cancer 54 Zevalin 54 Capecitabine 54 unresectable liver cancer 54 panobinostat 54 allogeneic stem cell 54 virological failure 54 Certican 54 metaglidasen 54 metastatic bladder 54 previously untreated follicular 54 dosing cohort 53 satraplatin Phase 53 refractory DLBCL 53 dimebon 53 letrozole 53 pemetrexed Alimta 53 tipranavir 53 multi kinase inhibitor 53 ToGA 53 gemcitabine Gemzar ® 53 sorafenib tablets 53 EOquin TM 53 naïve HCV 53 Cyclophosphamide 53 Platinol ® cisplatin 53 COU AA 53 APPRAISE 53 CYT# potent vascular disrupting 53 metastases 53 Hormone Refractory Prostate Cancer 53 carcinoma 53 denufosol 53 recurrent genital herpes 53 eculizumab 53 histologies 53 interferon beta 1b 53 liposomal formulation 53 dirucotide 53 Ophena TM 53 imatinib mesylate Gleevec 53 protease inhibitor 53 Evoltra TM 53 chemoradiation therapy 53 dose escalation trial 53 peritoneal carcinomatosis 53 HCV genotypes 53 Phase Ib study 53 Randomized Phase 53 nonmetastatic prostate cancer 53 Pralatrexate 53 tyrosine kinase inhibitor TKI 53 PD LID 53 refractory indolent non 53 Ceplene/IL-2 53 sunitinib Sutent 53 Paraplatin ® carboplatin 53 alkylating agents 53 immunotherapeutic agent 53 Zolinza 53 oral Hycamtin 53 Chronic Myeloid Leukemia 53 Interferon alfa 53 Golimumab 53 nonmetastatic 53 Alpharadin 53 Metastatic breast cancer 53 pCR 53 oral deforolimus 53 refractory CML 53 phase IIb trial 53 Brentuximab Vedotin SGN 53 relapsed leukemia 53 Triapine 53 Phase IIIb clinical 53 ZEVALIN 53 tesmilifene 53 Cotara 53 carboplatin chemotherapy 53 neratinib 53 Flu Cy 53 ancrod 53 Telintra 53 chemo radiotherapy 53 BCG refractory 53 Xelox 53 fallopian tube cancers 53 satraplatin 53 etoposide 53 immunomodulatory therapy 53 non metastatic resectable 53 adjuvant radiotherapy 53 RSR# 53 colorectal cancer CRC 53 lymphoid malignancies 53 Phase 1b 53 epirubicin 53 peginterferon alpha 2a 53 RSD# oral 53 MGd 53 pixantrone 53 angiogenesis inhibitor 53 Insegia 53 splenectomized patients 53 DCVax ® Brain 53 Pirfenidone 53 CIMZIA TM certolizumab pegol 53 COPAXONE R 53 sarcomas 53 chronic HBV 53 PROVENGE ® 53 pan HDAC inhibitor 53 antithrombotic 53 nucleoside analog 53 metastatic neuroendocrine tumors 53 CYC# 53 proteasome inhibitor 53 G CSF